[Therapeutic strategies in RP (retinitis pigmentosa): light at the end of the tunnel?].
Retinitis pigmentosa (RP) is a hereditary retinal dystrophy which leads to severe visual impairment or blindness and affects about 3.5/1000 of individuals in the industrial world. During the past decades, numerous animal models carrying mutations analogous to mutations in human RP have been studied to elucidate the molecular mechanisms leading to apoptotic photoreceptor cell death in this disease. Up to date, there is no effective treatment to influence the fatal outcome of RP. Recent progress in basic research promotes the development of new therapeutic strategies. In order to restore visual function in blind individuals, the development of electronic photoreceptor prosthesis is being investigated by several researchgroups. Other promising approaches are somatic gene therapy, the application of growth factors and/or pharmacological agents and the inhibition of photoreceptor cell death by interfering with the apoptotic pathway. However, a better understanding of the molecular events leading to cell loss due to photoreceptor apoptosis will be essential for the development of effective treatment.
Abegg
M
M
Labor für Zellbiologie der Netzhaut, Universitäts-Augenklinik Zürich.
Hafezi
F
F
Wenzel
A
A
Grimm
C
C
Remé
C E
CE
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D005786:Gene Expression Regulation; D016762:Genes, fos / Q000235:genetics; D015316:Genetic Therapy; D005858:Germany; D006801:Humans; D020007:Implants, Experimental / Q000639:trends*; D008839:Microelectrodes; D020419:Photoreceptor Cells, Vertebrate; D012160:Retina / Q000637:transplantation*; D012174:Retinitis Pigmentosa / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*